Dermata Therapeutics, Inc. (DRMA)

NCM – Real Time Price. Currency in USD

1.29

+0.21 (19.91%)

Market open: Aug 12, 2026, 2:08 PM EDT

1.61

+0.53 (49.06%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

11.08.2026

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 - - Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand - SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026. "Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company," commented Gerry Proehl, Dermata's Chairman, President, and CEO.

05.08.2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

- A new chapter in skincare has arrived - - This will be Dermata's first commercial product launch, planned for August 25, 2026 - - Join the waitlist at tomeskincare.com - SAN DIEGO, CA / ACCESS Newswire / August 5, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is planned to launch on August 25, 2026, with those on the waitlist getting early access to preorder. The launch of the Foundational Treatment represents a significant milestone in Dermata's strategic evolution toward becoming a consumer-focused, revenue-generating, skincare company.

Videos

No Data

There is no data to display

Press releases

11.08.2026

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

05.08.2026

Dermata Therapeutics, Inc. (DRMA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Videos

No Data

Press releases

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Videos

No Data

Press releases

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Search stocks

Dermata Therapeutics, Inc. (DRMA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Videos

No Data

Press releases

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Videos

No Data

Press releases

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment